References: 1. Harvey HA, Cream LR. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007;7(suppl 1):S7-S13. 2. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593-602. 3. Kinnane N. Burden of bone disease. Eur J Oncol Nurs. 2007;11(suppl):S28-S31. 4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520. 5. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493. 6. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 7. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664. 8. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12(suppl 20):6305s-6308s. 9. Keller ET,Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-1102. 10. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13. 11. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International Bone & Mineral Society Davos Workshops; March 9-14, 2008; Davos, Switzerland. Abstract 199. 12. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969. 13. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 14. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 15. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. V.2.2008. http://www.nccn.org. Accessed March 26, 2008. 17. Kyle RA, Yee GC, Somerfield MR,et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-2472.